RESULTS: A total of 4000 patients with HFrEF, HF with mildly reduced ejection fraction, and HF with improved ejection fraction will be enrolled in >40 Dutch centres with a follow-up of at least 3 years. Data collection will include demographics, physical examination and vital parameters, electrocardiogram, laboratory measurements, echocardiogram, medication, and quality of life. Detailed information on titration steps will be collected for the four GDMT drug classes. Information will include date, primary reason for change, and potential intolerances. The primary clinical endpoints are HF-related hospitalizations, HF-related urgent visits with a need for intravenous diuretics, all-cause mortality, and cardiovascular mortality.
CONCLUSIONS: TITRATE-HF is a real-world multicentre longitudinal registry that will provide unique information on contemporary GDMT implementation, sequencing strategies (order and speed), and prognosis in de novo, worsening, and chronic HF patients.
结果:共4000例HFrEF患者,射血分数轻度降低的HF,射血分数改善的HF将在>40个荷兰中心登记,随访至少3年。数据收集将包括人口统计,体检和重要参数,心电图,实验室测量,超声心动图,药物,和生活质量。将收集四种GDMT药物类别的滴定步骤的详细信息。信息将包括日期,改变的主要原因,潜在的不容忍。主要临床终点是HF相关的住院治疗,HF相关的紧急访问需要静脉利尿剂,全因死亡率,和心血管死亡率。
结论:TITRATE-HF是一个真实的多中心纵向注册中心,将提供有关当代GDMT实施的独特信息,测序策略(顺序和速度),和从头预测,恶化,和慢性HF患者。